This paper reviews China’s future fossil fuel supply from the perspectives of physical output and net energy output. Comprehensive analyses of physical output of fossil fuels suggest that China’s total oil productio...This paper reviews China’s future fossil fuel supply from the perspectives of physical output and net energy output. Comprehensive analyses of physical output of fossil fuels suggest that China’s total oil production will likely reach its peak, at about 230 Mt/year(or 9.6 EJ/year),in 2018; its total gas production will peak at around350 Bcm/year(or 13.6 EJ/year) in 2040, while coal production will peak at about 4400 Mt/year(or 91.9 EJ/year)around 2020 or so. In terms of the forecast production of these fuels, there are significant differences among current studies. These differences can be mainly explained by different ultimately recoverable resources assumptions, the nature of the models used, and differences in the historical production data. Due to the future constraints on fossil fuels production, a large gap is projected to grow between domestic supply and demand, which will need to be met by increasing imports. Net energy analyses show that both coal and oil and gas production show a steady declining trend of EROI(energy return on investment) due to the depletion of shallow-buried coal resources and conventional oil and gas resources, which is generally consistent with the approaching peaks of physical production of fossil fuels. The peaks of fossil fuels production, coupled with the decline in EROI ratios, are likely to challenge the sustainable development of Chinese society unless new abundant energy resources with high EROI values can be found.展开更多
The peritoneum is the most common site of recurrence of gastric cancer(GC).Early occult peritoneal metastasis is difficult to detect by imaging examination.Stratifying the risk of peritoneal metastasis in patients wit...The peritoneum is the most common site of recurrence of gastric cancer(GC).Early occult peritoneal metastasis is difficult to detect by imaging examination.Stratifying the risk of peritoneal metastasis in patients with different Lauren subtypes is of great clinical value.We performed a univariate Cox regression to identify those genes with prognostic value of overall survival(OS)and peritoneal-specified disease-free survival(psDFS)from the Gene Expression Omnibus database.The candidate genes were screened by the Subpopulation Treatment Effect Pattern Plot(STEPP)method.Propensity score matching(PSM)analysis was used to reduce the interference of confounders on the results.Based on the optimal cut-off values determined by the STEPP method,we found overexpression of three genes(HAND2-AS1,PRKAA2,and VLDLR)was correlated with shorter 1-year psDFS among patients with diffuse-type than that of patients with intestinal-type GC,and it is highly significant.Gene Set Enrichment Analysis(GSEA)potentially suggested that the three genes promote the early occurrence of peritoneal metastasis in patients with diffuse-type GC through glucose metabolism-related pathways.These three genes may be potential biomarkers.They can be used to assess the risk of peritoneal metastases to guide treatment decisions and follow-up strategies.展开更多
Comparing with lithofacies palaeogeography of several great plains,the authors analyzed four great plains in Quaternary diastrophism,the sedimentary facies,sedimentary environment and their evolution from the independ...Comparing with lithofacies palaeogeography of several great plains,the authors analyzed four great plains in Quaternary diastrophism,the sedimentary facies,sedimentary environment and their evolution from the independent embryonic and river system of ancient Heilongjiang finally to the Halar highland,Songnen Plain,Sanjiang Plain,the Xingkai Lake Plain and various river systems,collected the unification outside the system of Heilongjiang River to release into the sea,south ancient Xialiao River finally piracy Dongliao River,Xialiao River had released into the sea the ancient water law vicissitude and the evolved rule.展开更多
Background Perforating artery territorial infarction(PAI)caused by branch atheromatous disease(BAD)is prone to recurrence and early progression without an effective and well-documented antiplatelet treatment regimen.T...Background Perforating artery territorial infarction(PAI)caused by branch atheromatous disease(BAD)is prone to recurrence and early progression without an effective and well-documented antiplatelet treatment regimen.Tirofiban,an adjunctive antiplatelet agent,has shown great potential to treat acute ischaemic stroke.However,whether the combination of tirofiban and aspirin can improve the prognosis of PAI remains unclear.Aim To explore an effective and safe antiplatelet regimen for reducing the risk of recurrence and early neurological deterioration(END)in PAI caused by BAD by comparing the tirofiban and aspirin combination with placebo and aspirin combination.Methods Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction(STRATEGY)trial is an ongoing multicentre,randomised,placebo-controlled trial in China.Eligible patients shall be randomly assigned to receive standard aspirin with tirofiban or placebo on the first day and standard aspirin from days 2 to 90.The primary endpoint is a new stroke or END within 90 days.The primary safety endpoint is severe or moderate bleeding within 90 days.Discussion The STRATEGY trial will assess whether tirofiban combined with aspirin is effective and safe in preventing recurrence and END in patients with PAI.Trial registration number NCT05310968.展开更多
基金Project(2016YFB1100103)supported by the National Key Research and Development Program of ChinaProject(KC1703004)supported by the Science and Technology Planning Project of Changsha City,ChinaProject(2018ZZTS127)supported by the Fundamental Research Funds for the Central Universities of Central South University,China。
基金supported by the National Natural Science Foundation of China(Grant Nos.71503264,71373285,71303258)Humanities and Social Sciences Youth Foundation of the Ministry of Education of China(Grant Nos.15YJC630121,13YJC630148)+1 种基金Science Foundation of China University of Petroleum,Beijing(No.2462014YJRC024)the Major Program of the National Social Science Found of China(Grant No.13&ZD159)
文摘This paper reviews China’s future fossil fuel supply from the perspectives of physical output and net energy output. Comprehensive analyses of physical output of fossil fuels suggest that China’s total oil production will likely reach its peak, at about 230 Mt/year(or 9.6 EJ/year),in 2018; its total gas production will peak at around350 Bcm/year(or 13.6 EJ/year) in 2040, while coal production will peak at about 4400 Mt/year(or 91.9 EJ/year)around 2020 or so. In terms of the forecast production of these fuels, there are significant differences among current studies. These differences can be mainly explained by different ultimately recoverable resources assumptions, the nature of the models used, and differences in the historical production data. Due to the future constraints on fossil fuels production, a large gap is projected to grow between domestic supply and demand, which will need to be met by increasing imports. Net energy analyses show that both coal and oil and gas production show a steady declining trend of EROI(energy return on investment) due to the depletion of shallow-buried coal resources and conventional oil and gas resources, which is generally consistent with the approaching peaks of physical production of fossil fuels. The peaks of fossil fuels production, coupled with the decline in EROI ratios, are likely to challenge the sustainable development of Chinese society unless new abundant energy resources with high EROI values can be found.
基金This research was approved by National Natural Science Foundation of China(No.81972331)National Science and Technology Major Project of the Ministry of Science and Technology of China(No.2017ZX09304025).
文摘The peritoneum is the most common site of recurrence of gastric cancer(GC).Early occult peritoneal metastasis is difficult to detect by imaging examination.Stratifying the risk of peritoneal metastasis in patients with different Lauren subtypes is of great clinical value.We performed a univariate Cox regression to identify those genes with prognostic value of overall survival(OS)and peritoneal-specified disease-free survival(psDFS)from the Gene Expression Omnibus database.The candidate genes were screened by the Subpopulation Treatment Effect Pattern Plot(STEPP)method.Propensity score matching(PSM)analysis was used to reduce the interference of confounders on the results.Based on the optimal cut-off values determined by the STEPP method,we found overexpression of three genes(HAND2-AS1,PRKAA2,and VLDLR)was correlated with shorter 1-year psDFS among patients with diffuse-type than that of patients with intestinal-type GC,and it is highly significant.Gene Set Enrichment Analysis(GSEA)potentially suggested that the three genes promote the early occurrence of peritoneal metastasis in patients with diffuse-type GC through glucose metabolism-related pathways.These three genes may be potential biomarkers.They can be used to assess the risk of peritoneal metastases to guide treatment decisions and follow-up strategies.
文摘Comparing with lithofacies palaeogeography of several great plains,the authors analyzed four great plains in Quaternary diastrophism,the sedimentary facies,sedimentary environment and their evolution from the independent embryonic and river system of ancient Heilongjiang finally to the Halar highland,Songnen Plain,Sanjiang Plain,the Xingkai Lake Plain and various river systems,collected the unification outside the system of Heilongjiang River to release into the sea,south ancient Xialiao River finally piracy Dongliao River,Xialiao River had released into the sea the ancient water law vicissitude and the evolved rule.
基金supported by the following grants:The National Natural Science Foundation of China(no.81825007)Beijing Outstanding Young Scientist Program(no.BJJWZYJH01201910025030)+4 种基金Youth Beijing Scholar Program(no.010)Beijing Talent Project-Class A:Innovation and Development(no.2018A12)'National Ten-Thousand Talent Plan'-Leadership of Scientific and Technological InnovationNational Key R&D Program of China(no.2017YFC1307900,2017YFC1307905)Grand Pharmaceutical Group Co has been providing tirofiban and its placebo free of cost and without any limitations.
文摘Background Perforating artery territorial infarction(PAI)caused by branch atheromatous disease(BAD)is prone to recurrence and early progression without an effective and well-documented antiplatelet treatment regimen.Tirofiban,an adjunctive antiplatelet agent,has shown great potential to treat acute ischaemic stroke.However,whether the combination of tirofiban and aspirin can improve the prognosis of PAI remains unclear.Aim To explore an effective and safe antiplatelet regimen for reducing the risk of recurrence and early neurological deterioration(END)in PAI caused by BAD by comparing the tirofiban and aspirin combination with placebo and aspirin combination.Methods Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction(STRATEGY)trial is an ongoing multicentre,randomised,placebo-controlled trial in China.Eligible patients shall be randomly assigned to receive standard aspirin with tirofiban or placebo on the first day and standard aspirin from days 2 to 90.The primary endpoint is a new stroke or END within 90 days.The primary safety endpoint is severe or moderate bleeding within 90 days.Discussion The STRATEGY trial will assess whether tirofiban combined with aspirin is effective and safe in preventing recurrence and END in patients with PAI.Trial registration number NCT05310968.